Pipeline news
-
18 January 2019
Clearside Biomedical , Inc., a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from MAGNOLIA, an extension study of PEACHTREE, its pivotal Phase 3 trial of XIPERE™ (formerly “suprachoroidal CLS-TA”) in patients with macular edema associated with non-infectious uveitis, was presented by Pauline Merrill, MD during the winter symposium of the American Uveitis Society in Park City, UT. Dr. Merrill is a Partner at Illinois Retina Associates and Section Director of Uveitis in the Department of Ophthalmology at Rush University Medical Center .
-
Syndax Highlights 2019 Clinical and Corporate Outlook
07 January 2019
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today provided a 2019 clinical and corporate outlook.
-
Healthcare Executive from Amazon Joins binx health Board of Directors
07 January 2019
binx health, a pioneer in convenient health, today announced that it has appointed Samar Parikh to its Board of Directors. Mr. Parikh has held various leadership positions within Amazon, including as an early catalyst behind its entry into healthcare. Parikh was also instrumental in the company's recent acquisition of PillPack. His roles at Amazon have included Global Leader, Business Development & Strategy (Consumables & Consumer Healthcare) and General Manager, CPG, Consumer Healthcare, and Consumer Healthcare Innovation, where he was responsible for managing Amazon's retail businesses across consumer-packaged goods, consumer healthcare and medical devices.
-
03 January 2019
Tragara Pharmaceuticals Inc. today announced the appointment of Scott Megaffin as Chief Executive Officer and a member of the Board of Directors effective immediately. Megaffin brings extensive leadership experience in clinical stage companies in oncology, specialty and critical care. He replaces Tom Estok, who will remain active with the company as an advisor and continue in his role on the Board of Directors.
-
19 December 2018
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced that it has submitted a New Drug Application (“NDA”) for XIPERETM to the U.S. Food and Drug Administration (“FDA”) for the treatment of macular edema associated with uveitis.
-
18 December 2018
Patients wondering if they have the sexually transmitted infections ("STI") chlamydia or gonorrhea may soon be able to get the results in about 30 minutes, according to new research funded through the National Institutes of Health. The binx health (formerly Atlas Genetics) result could lead to immediate treatment and an associated reduction in the spread of the infection. The World Health Organization has identified chlamydia and gonorrhea, among the most prevalent STIs, as organisms without an available point-of-care (POC) test.
-
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
12 December 2018
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of $3.75 per share. The total public offering size is expected to be $45.0 million , before deducting the underwriting discounts and commissions and other offering expenses payable by the Company.
-
Marinus Pharmaceuticals Announces Public Offering of Common Stock
11 December 2018
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Marinus. Jefferies LLC and Leerink Partners LLC are acting as joint bookrunning managers for the offering. Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock.
-
Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression
10 December 2018
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV) (the Magnolia Study) and oral (the Amaryllis Study) in women with postpartum depression (PPD). Based on these results, the Company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens.
-
04 December 2018
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that ganaxolone data from its Phase 2 clinical trial in pediatric genetic epilepsies, CDKL5 Deficiency Disorder (CDD) and PCDH19-related pediatric epilepsy (PCDH19 epilepsy) were presented at the American Epilepsy Society ( AES ) Annual Meeting in New Orleans on December 2 and 3, 2018.
